Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-02

Study Completion Date

2024-02-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

NCT01794520

Relapsed/Refractory Multiple Myeloma

COMPLETED PHASE1/PHASE2

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

NCT02951117

Multiple Myeloma

WITHDRAWN PHASE1

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

NCT02899052

Multiple Myeloma

ACTIVE_NOT_RECRUITING PHASE2

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597

Relapsed/Refractory Multiple Myeloma

COMPLETED PHASE3

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT02633059

Loss of Chromosome 17p Recurrent Plasma Cell Myeloma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of venetoclax in combination with ixazomib citrate (ixazomib) and dexamethasone in patients with relapsed multiple myeloma (MM). (Phase 1)

SECONDARY OBJECTIVES:

I. To describe toxicities associated with venetoclax, in combination with ixazomib and dexamethasone in patients with relapsed MM. (Phase 1)

TERTIARY OBJECTIVES:

I. To explore levels of BCL-2 family member proteins (BCL-2, BCL-x, MCL-1) on bone marrow biopsies using ribonucleic acid sequencing (RNASeq) and immunohistochemistry.

OUTLINE: This is a phase I, dose-escalation study of venetoclax followed by a phase II study.

Patients receive venetoclax orally (PO) daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 or 6 months for 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Plasma Cell Myeloma T(11;14)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (venetoclax, ixazomib citrate, dexamethasone)

Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Dexamethasone

Intervention Type DRUG

Given PO

Ixazomib Citrate

Intervention Type DRUG

Given PO

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Venetoclax

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

Given PO

Intervention Type DRUG

Ixazomib Citrate

Given PO

Intervention Type DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Venetoclax

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aacidexam Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone MLN-9708 MLN9708 Ninlaro ABT-0199 ABT-199 ABT199 GDC-0199 RG7601 Venclexta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Phase 1: Relapsed MM with at least one prior line of therapy and should have received a proteasome inhibitor and an immunomodulatory drug
* Phase 2: 1-3 prior lines of therapy and should have received a proteasome inhibitor and an immunomodulatory drug
* Obtained =\< 14 days prior to registration: Calculated creatinine clearance (using Cockcroft-Gault equation) \>= 30 mL/min
* Obtained =\< 14 days prior to registration: Absolute neutrophil count (ANC) \>= 1000/uL (without growth factor support)
* Obtained =\< 14 days prior to registration: Un-transfused platelet count \>= 75000/uL (\>= 50,000/uL if marrow plasma cells \[PC\]% \> 50%)
* Obtained =\< 14 days prior to registration: Hemoglobin \>= 8.0 g/dL
* Obtained =\< 14 days prior to registration: Total bilirubin =\< 1.5 x upper limit of normal (ULN)
* Obtained =\< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN
* Obtained =\< 14 days prior to registration: Alkaline phosphatase =\< 750 U/L
* Expansion cohort only: Plasma cell fluorescence in situ hybridization (FISH) test demonstrating presence of t(11;14)
* Measurable disease of multiple myeloma as defined by at least ONE of the following:

* Serum monoclonal protein \>= 1.0 g/dL
* \> 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
* Serum immunoglobulin free light chain \>= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* Provide written informed consent
* Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only
* Willing to follow strict birth control measures as suggested by the study

* Female patients: If they are of childbearing potential, must agree to one of the following:

* Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception)
* Male patients: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:

* Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR
* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception)
* Life expectancy \>= 12 weeks
* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
* Willing to provide research bone marrow aspirate specimen

Exclusion Criteria

* Diagnosed or treated for another malignancy =\< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
* Any of the following:

* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease
* Other concurrent chemotherapy or any ancillary therapy considered investigational

* NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
* Peripheral neuropathy \>= grade 2 on clinical examination or grade 1 with pain during the screening period
* Major surgery =\< 14 days prior to study registration
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
* Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis
* Administration of a strong or moderate CYP3A inhibitor or inducer =\< 14 days prior to registration
* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
* Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
* Failure to have fully recovered (i.e., =\< grade 1 toxicity) from the reversible effects of prior chemotherapy
* Radiotherapy =\< 14 days prior to registration; Note: If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib
* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
* Previous treatment with ixazomib, or participated in a blinded study with ixazomib
* Live-virus vaccines =\< 28 days prior to registration
* Heart failure \> New York Heart Association (NYHA) class II

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No